News headlines about Ritter Pharmaceuticals (NASDAQ:RTTR) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ritter Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.7062460151673 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
RTTR has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. Maxim Group reiterated a “hold” rating on shares of Ritter Pharmaceuticals in a report on Friday, August 4th. Finally, Roth Capital set a $2.00 target price on shares of Ritter Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 23rd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Ritter Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $2.92.
Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) opened at $0.34 on Friday. Ritter Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $3.75.
Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.14). research analysts expect that Ritter Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/11/17/ritter-pharmaceuticals-rttr-earning-somewhat-favorable-news-coverage-report-finds.html.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.